Weishi 2019 Results: China Grows 16% Le Weima Shines

Pharmaceutical Network May 26 - Recently, Japanese pharmaceutical companies have released 2019 financial resultsToday, let's take a look at the performance of MrWeissi last yearAs the world's top 50 pharmaceutical companies, although not already rushed into the top 10 Takeda so dazzling, but also well-known Japanese pharmaceutical companies, it is still worth paying attention toduring the 2019 reporting period (April 1 - March 31 of the following year), Aishi's global revenue was 642.8 billion yen (44.590 billion yuan, 1 RMB15.60 yen, the same as the same as the same), an increase of 8.21% yoyInvestment in research and development was 140.1 billion yen (8.981 billion yuan), down 3.25 percent year-on-year, mainly due to the company's use of a cooperative research and development model to reduce research and development costsChart 1: Aishi's financial situation in 2019 (in one billion yen)Source: Aishi's earningsthe main driver of revenue growth during the reporting period was the continued growth in revenue from Lenvima, which offset the decline in revenue, including the transfer of generic son-in-ones in April last yearSpecifically, LeWeima's sales for the current fiscal year were RMB7,038 million, up 78.75 percent year-on-yearIn addition to sales revenue, LeWeima also has a one-time payment on landmark revenue and options from Mercado, which contributed to the company's earnings growthIn addition to LeWeima, Fycompa's sales also increased by 31% to 1.622 billion yuan from 1.237 billion yuanIn contrast, Halaven's sales fell slightly, from 2,747 million yuan to 2.577 billion yuan, mainly due to a slight decline in sales in Japan, Asia and Latin AmericaChart 2: Aishi's main product salesSource: Aishi's earnings report
in terms of income sources, the top three regions for revenue are Japan, the United States and China However, Aishi's revenue fell in Japan, while revenue growth in the U.S and China was double-digit, especially in the U.S region, which grew by as much as 31 percent In China, Aishi's revenue was 77 billion yen (4,936 million yuan), up 16.14 percent year-on-year, the second-largest growth rate after the U.S Chart 3: Weishi's revenue in different regions
Source: Weishi's earnings in the Chinese market, Le Weima's performance is very eye-catching In September 2018, NMPA officially approved leWeima (Lunvatini) to be listed in China for first-line treatment of advanced liver cancer; Less than two years after its listing, LeWeima's sales have grown to 853 million yuan from 199 million yuan in 2018, and the market is strong China is a large liver cancer country, each year 466,000 new liver cancer patients, of which 80% are patients with advanced liver cancer, the death toll of 422,000, a serious threat to people's lives and In this large market context, it is expected that The sales after the continued release of LeWeima will be very substantial 　　Halaven and Fycompa were both launched in China at the end of last year, so sales are low and remain to be seen In addition, the domestic market also achieved 4.3% growth But at present, the second batch of collection has begun to implement, it is expected that the bid of the next-up to the Company may face severe market challenges Chart 4: 2019 Weishi's product sales in China
source: Weishi Financial Report, Zhongkang Industrial Capital Research Center Le Weima as The current seed products of Weishi, has been gradually exerting strength This year, the product is expected to further expand the market so that it can be released quickly in the U.S market, on the one hand, LeWeima will increase dynamic growth by increasing its market share of first-line non-recytoctive hepatocellular carcinoma (uHCC) and endometrial cancer (EC), and on the other hand, trials of the product's combination of KEYTRUDA treatment are being reviewed, which is preparing for the expansion of first-line HCC indications in the Chinese market, LeWeima will introduce a new Patient Assistance Program (PAP) to expand the market In addition, in December last year, the drug has submitted a new application for differentiated thyroid cancer (DTC) indications, and has been accepted by the NMPA, the drug's second adaptation in China, which is expected to be approved by the end of this year or early next year as for other markets, LeWeima will also have a corresponding expansion plan In 2020, LeWeima's target sales will be 158 billion yen, or about 10.1 billion yuan If it can be implemented according to the plan, I believe that in the coming year, Le Weima to achieve revenue of more than 10 billion yuan is not difficult.